Lysulin: When Hashtags Became Drug Evidence

Which hashtags did FDA quote in the Lysulin letter?

FDA quoted the hashtag string "#type2diabetic #diabetescare ... #insulindependent #diabetes #insulinresistance" from a Lysulin, Inc. Instagram post in its September 7, 2021 warning letter, per FDA's letter to Lysulin, Inc. (MARCS-CMS 614517). The agency read the tags as label copy — audience-facing evidence of what the product was intended to do, not decoration attached after the fact.

The same letter quoted Lysulin's own website copy: "The combination and high level of these active ingredients have been shown to help maintain healthy A1c blood sugar levels in diabetics and prediabetics." FDA also cited the blunter lines "[D]aily serving of patented Lysulin to reduce blood glucose" and "Reduces Glucose in the blood stream." Three claim types, one letter.

We checked FDA's letter and found it was one of ten issued that same day, all citing diabetes claims.

How can a hashtag establish intended use under 21 CFR 201.128?

A hashtag counts as intended-use evidence because 21 CFR 201.128 defines intent by what a company communicates, not by the format it uses. The regulation states that intent "may, for example, be shown by labeling claims, advertising matter, or oral or written statements," per 21 CFR 201.128 — and FDA treats a hashtag as advertising matter the same way it treats a headline.

Under 21 CFR 101.93(g)(2)(ii), a supplement makes a disease claim if it targets the characteristic signs or symptoms of a named condition "using scientific or lay terminology." A hashtag naming a diagnosis — #type2diabetic, #insulindependent — is lay terminology aimed at exactly that population. It doesn't need a verb attached to function as a claim; you don't get credit for silence around the noun.

FDA's own preamble to the 2000 structure/function rule spelled out the permitted and forbidden versions of a nearly identical sentence. Forbidden: "Use as part of your diet when taking insulin to help maintain a healthy blood sugar level." Permitted: "use as part of your diet to help maintain a healthy blood sugar level." FDA explained the fix in plain terms in its 2000 final rule: "Deleting the reference to the drug, insulin, would remove the implication."

We could not verify how many of FDA's other diabetes warning letters also cite hashtags specifically; the agency's search index doesn't tag letters by evidence type, so this remains a single documented instance rather than a proven pattern across the niche.

Which social testimonials did FDA attribute to the brand?

FDA cited a customer testimonial posted on Lysulin's own social accounts reporting an HbA1c reading fell from 10.5% to 9.5%. HbA1c — a blood test measuring average blood sugar over roughly three months — is the standard diagnostic marker for diabetes, so quoting it in a testimonial is effectively a lab-value efficacy claim delivered in someone else's voice.

FDA didn't distinguish between a claim the brand wrote and a claim a customer left in the comments. Once a testimonial sits on a channel the company controls, the agency treats it as label copy — the same theory it used when a Facebook Like became an endorsement for BergaMet North America, where the brand replied "that is AMAZING Lori!" to a customer claiming a supplement fixed lab numbers a statin couldn't.

Neither testimonial needed the brand's disclaimer removed to become evidence.

Does organic content carry the same exposure as paid creative?

Yes — organic and unpaid content carries the same exposure as a paid ad, and in practice it may carry more, because nobody reviews a caption before it goes live the way a compliance team reviews ad copy. We compared four FDA letters side by side, and each pulled its primary evidence from a different social channel — Instagram, a Facebook comment, a blog post, and a retail listing.

Most operators assume paid creative carries the real risk because it's the one thing a compliance team actually reviews before money moves, and unpaid content feels like exhaust — captions nobody signed off on, posted by whoever runs the account that week. The letter record argues close to the opposite. Organic posts skip that review gate entirely, they sit indexed on a domain the brand owns long after any campaign budget stops, and FDA has repeatedly built its strongest evidence from exactly this material rather than from the ad unit itself — a pattern visible in the blog posts a brand never treated as advertising that became the drug-intent citation in more than one warning letter, this one included.

What did FDA mean by noting the FTC reviewed the same sites?

FDA meant exactly what it said: two separate federal agencies looked at the same web pages in the same month, and each can act on what it found independently. The letter states plainly, "the Federal Trade Commission reviewed your websites in August 2021" — one sentence, no further explanation attached, because the two agencies don't need a joint theory to each have jurisdiction over the same claim.

The pattern isn't unique to Lysulin. FDA's letter to Live Good Inc. over its Berry Gen collagen product cites the brand's Facebook page, Instagram and Amazon storefront as intended-use evidence and carries the identical line about an FTC review the same month, per the FTC's copy of that warning letter.

Fixing one agency's finding doesn't clear the other's.

How far does this reach into influencer and UGC content?

It reaches as far as anything published on a channel the brand controls or amplifies, which includes influencer posts, comment replies, and reviews left on a retail listing. FDA's letter to Fibromyalgia Treatment Group cited both the product's name and consumer testimonials as independent evidence of intended use, treating each as its own line item rather than folding them into a single claim.

Advertiser liability doesn't stop at content the brand itself wrote. When an affiliate or influencer makes a claim the brand's own compliance team would never approve, the exposure still lands on the offer — the same lesson that plays out when your affiliate's ad becomes your warning letter.

Your quiz funnel or review widget isn't exempt just because a customer wrote the words.

What social hygiene does a glucose offer need before scaling?

If you're scaling a glucose or A1c offer, audit its social surface before spend increases, not after a letter arrives — and counting warning letters by niche tells you less about that exposure than actually reading what evidence FDA cited in each one.

If a letter does land anyway, the response sequence matters as much as the content did. The same triage steps that apply when an FDA warning letter hits a peptide or GLP-1 offer apply here: preserve evidence, stop the specific claim, and don't assume deleting the post undoes the citation.

• Pull every hashtag containing a diagnosis word — #diabetic, #insulinresistance, #type2 — from Instagram, TikTok and X captions, not just the paid ad copy.
• Screenshot and archive customer testimonials that cite lab values (A1c, fasting glucose) before removing them, since your own comment replies can count as endorsement.
• Audit blog posts and ingredient pages for disease language even where the product landing page itself reads clean.
• Check the Amazon or retail listing separately — FDA has cited marketplace copy as its own independent evidence line in multiple letters.
• Read what a prior letter actually quoted for a competitor running a near-identical formula before building your own claims set around it.

Quick decision checklist

Use this page as a decision aid, not a generic blog post. The practical question is whether the reader needs faster evidence about what is already working in VSL-driven direct response, especially across nutra, supplements, GLP-1, weight loss, blood sugar, and adjacent high-intent health markets.

Daily Intel Service is most relevant when the next decision depends on active market examples: which hook to test, which claim style is risky, which funnel structure is common, which language market is moving, and whether a competitor's creative is likely early, scaling, or already saturated.

• Start with the TL;DR if you need the direct answer.
• Use the table to compare trade-offs quickly.
• Use the FAQ for answer-engine-ready summaries.
• Use the CTA when the decision requires live VSL and ad examples instead of theory.

Daily Intel's coverage advantage

Daily Intel Service is positioned around category-leading variety and actionability: one of the broadest direct-response catalogs of VSLs and ad creatives across blackhat, greyhat, and whitehat advertising patterns, with enough context to understand what the advertiser is doing beyond the visible creative. The practical difference is that members are not just seeing a screenshot; they are seeing the VSL, the ad, the funnel path, the transcript, the UTM context, and the research notes that turn the asset into a decision.

This matters because direct-response affiliates do not operate in one clean category. A weight-loss campaign may use a whitehat compliance ad, a greyhat pre-lander, a more aggressive VSL, and a checkout path designed around upsells and recovery. A useful intelligence platform needs to capture that spectrum instead of pretending every winning campaign looks like a public brand ad.

Blackhat, whitehat, and multilingual signal coverage

Daily Intel tracks patterns across both blackhat-style and whitehat-style campaigns so operators can understand the market without blindly copying risk. Whitehat examples help with durability and compliance review; blackhat and greyhat examples reveal pressure points, hooks, mechanisms, and funnel structures that may be driving spend but require careful adaptation before use.

The catalog is also built for global operators, with VSL and ad references spanning 14+ languages and different local idioms. That is a key advantage for Brazilian, LATAM, European, MENA, Indian, and non-native English affiliates who need to see how the same market desire is translated across cultures instead of only studying US English ads.

How to use the intelligence responsibly

The goal is modeling, not copying. Use Daily Intel to understand structure: hook, mechanism, proof, claim intensity, funnel depth, offer economics, and saturation stage. Then build original creative, review claims, and adapt the angle to the traffic source, country, language, and compliance requirements of the campaign.

A strong workflow compares multiple examples before acting. If the same mechanism appears across several languages, several advertisers, and several funnel variants, it may be a durable market signal. If the example appears only once or depends on an aggressive claim, treat it as a research clue rather than a campaign template.

• Model structure, not protected creative assets.
• Separate whitehat durability from blackhat persuasion pressure.
• Compare US English examples against LATAM, European, and other language variants.
• Use transcripts and funnel notes to build original briefs.
• Keep compliance review separate from market research.

Methodology and source context

Daily Intel pages are written from a research workflow that reviews active VSLs, Meta ad creatives, transcripts, UTMs, funnel paths, checkout steps, upsells, recovery sequences, and compliance-sensitive claim patterns. The goal is to explain observable market behavior, not to provide legal, medical, or platform policy advice.

For external context, readers should compare advertising and research decisions against authoritative primary references such as FTC health claims guidance, Meta advertising standards, and Meta Ad Library. Daily Intel adds the proprietary direct-response layer: blackhat, greyhat, and whitehat campaign pattern comparison across VSL-heavy niches and 14+ language markets.

For deeper evaluation, continue through Nutra niche intelligence directory, Muscle and Sports Nutrition Offers: Market and Legal Boundaries, Pet Supplement Offers: A Different Regulator, A Different Buyer, Gout and Uric Acid Offers: Small, Sharp, and Tightly Capped, The Claim Ceiling by Condition: How High Each Niche Lets You Go, and GLP-1 affiliate marketing intelligence. These related Daily Intel pages connect this topic to the relevant methodology, pricing, trust context, comparison path, or niche workflow.